Iniciar Sesión Regístrate abrir menu

Bibliografía Científica

Artículos por temáticas

En este apartado encontrará una actualización mensual de Enfermedad de Alzheimer y Demencias

8059 ARTÍCULOS , VIENDO DEL 6736 AL 6750

Potential application of endocannabinoid system agents in neuropsychiatric and neurodegenerative diseases-focusing on FAAH/MAGL inhibitors

Ren SY, Wang ZZ, Zhang Y, Chen NH.

Acta Pharmacol Sin. 2020 Oct;41(10):1263-1271. doi: 10.1038/s41401-020-0385-7. Epub 2020 Mar 18.

5-lipoxygenase pathway and its downstream cysteinyl leukotrienes as potential therapeutic targets for Alzheimer's disease

Chen F, Ghosh A, Lin J, Zhang C, Pan Y, Thakur A, Singh K, Hong H, Tang S.

Brain Behav Immun. 2020 Aug;88:844-855. doi: 10.1016/j.bbi.2020.03.022. Epub 2020 Mar 25.

Potential for Treatment of Neurodegenerative Diseases with Natural Products or Synthetic Compounds that Stabilize Microtubules

Miller JH, Das V.

Curr Pharm Des. 2020;26(35):4362-4372. doi: 10.2174/1381612826666200621171302.

Progress toward Alzheimer's disease treatment: Leveraging the Achilles' heel of Aβ oligomers?

Fantini J, Chahinian H, Yahi N.

Protein Sci. 2020 Aug;29(8):1748-1759. doi: 10.1002/pro.3906. Epub 2020 Jul 13.

Rapid improvement in Alzheimer's disease symptoms following fecal microbiota transplantation: a case report

Hazan S.

J Int Med Res. 2020 Jun;48(6):300060520925930. doi: 10.1177/0300060520925930.

Glibenclamide as a neuroprotective antidementia drug

Zubov A, Muruzheva Z, Tikhomirova M, Karpenko M.

Arch Physiol Biochem. 2022 Dec;128(6):1693-1696. doi: 10.1080/13813455.2020.1789170. Epub 2020 Jul 11.

New antipsychotic drugs for the treatment of agitation and psychosis in Alzheimer's disease: focus on brexpiprazole and pimavanserin

Caraci F, Santagati M, Caruso G, Cannavò D, Leggio GM, Salomone S, Drago F.

F1000Res. 2020 Jul 8;9:F1000 Faculty Rev-686. doi: 10.12688/f1000research.22662.1. eCollection 2020.

Towards early disease modification of Parkinson's disease: a review of lessons learned in the Alzheimer field

Smedinga M, Darweesh SKL, Bloem BR, Post B, Richard E.

J Neurol. 2021 Feb;268(2):724-733. doi: 10.1007/s00415-020-10162-5. Epub 2020 Aug 18.

Current Aspects of the Endocannabinoid System and Targeted THC and CBD Phytocannabinoids as Potential Therapeutics for Parkinson's and Alzheimer's Diseases: a Review

Cooray R, Gupta V, Suphioglu C.

Mol Neurobiol. 2020 Nov;57(11):4878-4890. doi: 10.1007/s12035-020-02054-6. Epub 2020 Aug 19.

Potential Role of Natural Polyphenols against Protein Aggregation Toxicity: In Vitro, In Vivo, and Clinical Studies

Henríquez G, Gomez A, Guerrero E, Narayan M.

ACS Chem Neurosci. 2020 Oct 7;11(19):2915-2934. doi: 10.1021/acschemneuro.0c00381. Epub 2020 Sep 11.

Antidiabetic drugs for Alzheimer's and Parkinson's diseases: Repurposing insulin, metformin, and thiazolidinediones

Cardoso S, Moreira PI.

Int Rev Neurobiol. 2020;155:37-64. doi: 10.1016/bs.irn.2020.02.010. Epub 2020 Aug 11.

Challenges and Opportunities of Deferoxamine Delivery for Treatment of Alzheimer's Disease, Parkinson's Disease, and Intracerebral Hemorrhage

Farr AC, Xiong MP.

Mol Pharm. 2021 Feb 1;18(2):593-609. doi: 10.1021/acs.molpharmaceut.0c00474. Epub 2020 Oct 9.

A comprehensive review of monoamine oxidase inhibitors as Anti-Alzheimer's disease agents: A review

Manzoor S, Hoda N.

Eur J Med Chem. 2020 Nov 15;206:112787. doi: 10.1016/j.ejmech.2020.112787. Epub 2020 Sep 1.

Target Enzymes Considered for the Treatment of Alzheimer's Disease and Parkinson's Disease

Kim N, Lee HJ.

Biomed Res Int. 2020 Nov 9;2020:2010728. doi: 10.1155/2020/2010728. eCollection 2020.

Sirtuins and Their Implications in Neurodegenerative Diseases from a Drug Discovery Perspective

Yeong KY, Berdigaliyev N, Chang Y.

ACS Chem Neurosci. 2020 Dec 16;11(24):4073-4091. doi: 10.1021/acschemneuro.0c00696. Epub 2020 Dec 5.

Actualización mensual Regístrese para recibir los avisos de actualización

Si quiere recomendar un artículo/publicación para completar este apartado puede hacerlo a través del formulario de contacto para su valoración.

En ningún caso la información facilitada constituye asesoramiento por parte de Zambon

Con el aval de:

Logo SEN Logo WIS

En colaboración con:

Zambon Neurociencias